AKT1 and gastric cancer: One of the first study evaluating the block of PI3K-AKT-mTOR pathway in GC is the GRANITE-1 Trial [66], a phase III study in which 656 GC patients who progressed after previous one or two lines of systemic chemotherapy were randomized between everolimus (a mTOR inhibitor) or placebo.